Featured Research

from universities, journals, and other organizations

New Advance In Lung Cancer Treatment

Date:
April 25, 2007
Source:
University Hospitals of Cleveland
Summary:
Researchers have developed methods for treating lung cancer cells that have become resistant to new anti-cancer agents, such as Tarceva (erlotinib). Using a new second-generation of Tarceva-like medications, researchers can overcome the drug resistance.

Researchers at the Ireland Cancer Center of University Hospitals Case Medical Center have developed methods for treating lung cancer cells that have become resistant to new anti-cancer agents.

Related Articles


Led by Balazs Halmos, MD, hematologist/oncologist with the Ireland Cancer Center, the research team followed up on their previous study, published in the New England Journal of Medicine, which found that lung cancer cells can become resistant to novel targeted agents, such as Tarceva (erlotinib), a medication in widespread use for non-small-cell lung cancer (NSCLC).

Tarceva is among a new generation of cancer therapies that disrupt the molecular target responsible for stimulating tumor growth. The drug targets the receptor for the epidermal growth factor protein (EGFR) to halt the spread of cancer cells. Clinical applications of the new drug initially yielded good results with approximately 10 percent of patients experiencing complete remission of their disease.

However, in spite of the therapy's initial success, patients inevitably suffered a relapse of their disease. Dr. Halmos' studies confirmed the existence of a mutation, and insertion of this mutation into test cells rendered them resistant to Tarceva. These cells became resistant by undergoing a miniscule molecular change in the EGFR protein that the medication targets.

Further analysis revealed that the newly identified mutation was altering the protein's drug-binding pocket and thereby changing the "keyhole" so that the "key" -- Tarceva -- no longer fit. The researchers found that new second-generation Tarceva-like medications can overcome this change and such drugs are now in development, including in clinical trials at the Ireland Cancer Center.

In this latest study, that received an award at the annual American Association for Cancer Research (AACR) meeting where it was presented earlier this month, Dr. Halmos and his team were able to predict molecular changes the tumors might take next to become resistant to this new class of agents. "We tried to outsmart tumors by anticipating their next moves," says Dr. Halmos, a lung cancer specialist and Assistant Professor of Medicine at Case Western Reserve University School of Medicine. "This research revealed a number of new changes that EGFR can undergo that leads to resistance and also found ways to conquer this next generation of mutants."

The research team developed compounds to overcome the resistance with innovative combinations of medications. "Using these combinations early on can prevent resistance," explains Dr. Halmos. "Through this research, we are redefining our tools and anticipating ways to fight lung cancer."


Story Source:

The above story is based on materials provided by University Hospitals of Cleveland. Note: Materials may be edited for content and length.


Cite This Page:

University Hospitals of Cleveland. "New Advance In Lung Cancer Treatment." ScienceDaily. ScienceDaily, 25 April 2007. <www.sciencedaily.com/releases/2007/04/070423155106.htm>.
University Hospitals of Cleveland. (2007, April 25). New Advance In Lung Cancer Treatment. ScienceDaily. Retrieved January 29, 2015 from www.sciencedaily.com/releases/2007/04/070423155106.htm
University Hospitals of Cleveland. "New Advance In Lung Cancer Treatment." ScienceDaily. www.sciencedaily.com/releases/2007/04/070423155106.htm (accessed January 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, January 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Are We Winning The Fight Against Ebola?

Are We Winning The Fight Against Ebola?

Newsy (Jan. 29, 2015) The World Health Organization announced the fight against Ebola has entered its second phase as the number of cases per week has steadily dropped. Video provided by Newsy
Powered by NewsLook.com
Measles Scare Sends 66 Calif. Students Home

Measles Scare Sends 66 Calif. Students Home

AP (Jan. 29, 2015) Officials say 66 students at a Southern California high school have been told to stay home through the end of next week because they may have been exposed to measles and are not vaccinated. (Jan. 29) Video provided by AP
Powered by NewsLook.com
Group Encourages Black Moms to Breastfeed

Group Encourages Black Moms to Breastfeed

AP (Jan. 29, 2015) A grassroots effort is underway in several US cities to encourage more black women to breastfeed their babies by teaching them the benefits of the age-old practice, which is sometimes shunned in African-American communities. (Jan. 29) Video provided by AP
Powered by NewsLook.com
Sugary Drinks May Cause Early Puberty In Girls, Study Says

Sugary Drinks May Cause Early Puberty In Girls, Study Says

Newsy (Jan. 28, 2015) Harvard researchers found that girls who consumed more than 1.5 sugary drinks a day had their first period earlier than those who drank less. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins